Core Viewpoint - Zhongsheng Pharmaceutical's subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., has received a drug registration certificate for the innovative drug Anladiwei tablets (brand name: Anruiwei®) from the Macao SAR government, indicating a significant advancement in flu treatment options [1] Group 1 - Anladiwei tablets have shown superior results in a Phase III clinical trial against oseltamivir capsules and placebo, with significant improvements in key endpoints such as time to alleviation of flu symptoms (TTAS) and other viral indicators [1] - The median TTAS and fever relief time for Anladiwei tablets were nearly 10% shorter compared to the oseltamivir group, demonstrating its efficacy [1] - Anladiwei tablets maintain strong inhibitory effects against oseltamivir and mabosavir-resistant viral strains, providing a better treatment option for patients and addressing the issue of antiviral resistance [1] Group 2 - The approval for Anladiwei tablets to be sold in Macao is expected to benefit more flu patients, offering safe and effective treatment choices for physicians and patients alike [1]